PCSK9 and atherosclerosis: In recent years, experimental and clinical evidence have suggested that the beneficial effects of statins, ezetimibe or PCSK9 inhibitors against atherosclerosis might be due to cholesterol-independent effects (improving endothelial function, stabilizing atherosclerotic plaques, attenuating vascular and myocardial remodeling, and inhibiting vascular inflammation, oxidation, and thrombosis) [19].